CPT code 81329 covers laboratory testing to detect deletions in the SMN1 (survival motor neuron 1) gene and may include analysis of the SMN2 gene. This genetic test is clinically important for diagnosing or supporting the diagnosis of spinal muscular atrophy (SMA) and related neuromuscular conditions where SMN1 deletions are etiologic. As molecular diagnostics become more central to precision medicine, accurate coding for SMN1/SMN2 analysis affects access to testing, billing accuracy, and epidemiologic tracking of hereditary neuromuscular disorders nationwide.

Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for SMN1 deletion testing, the typical service setting and workflow implications for laboratories, and payer coverage landscape summaries. The publication also presents benchmarking and policy-relevant considerations such as coding clarity, site-of-service implications for the technical component, and common modifiers used with laboratory services. Data not available in the input will be noted where applicable.

This summary is intended for laboratory billing staff, compliance officers, and policy analysts seeking a concise national view of CPT code 81329, its clinical role, and the payer environment affecting reimbursement and utilization.